- ESHAP Salvage Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
-
Choi CW, Paek CW, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS
- KMID: 1127252
- J Korean Med Sci.
- 2002 Oct;17(5):621-624.
- doi: 10.3346/jkms.2002.17.5.621
The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma... -
- CITED
-
- Close
- SHARE
-
- Close
- ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkins Lymphoma: A Single Center Experience
-
Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP, Huh J, Kim SB, Kim SW, Lee JL, Suh C
- KMID: 759841
- Korean J Intern Med.
- 2006 Sep;21(3):159-164.
- doi: 10.3904/kjim.2006.21.3.159
BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin 's Lymphoma
-
Kim JG, Sohn SK, Kim DH, Baek JH, Park TI, Lee KB
- KMID: 1778563
- J Korean Med Sci.
- 2004 Dec;19(6):820-825.
- doi: 10.3346/jkms.2004.19.6.820
The main objectives of the current study were to evaluate the efficacy and safety of a CEOP-E regimen for patients with aggressive non-Hodgkin's lymphoma (NHL). Fifty-one consecutive patients with newly... -
- CITED
-
- Close
- SHARE
-
- Close
- Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
-
Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS
- KMID: 1785660
- Korean J Intern Med.
- 2010 Mar;25(1):86-92.
- doi: 10.3904/kjim.2010.25.1.86
BACKGROUND/AIMS: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus... -
- CITED
-
- Close
- SHARE
-
- Close
- A Successful Treatment of Relapsed Primary CNS Lymphoma Patient with Intraventricular Rituximab Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue
-
Hong SJ, Kim JS, Chang JH, Kim KM, Kim SJ, Lee HW, Cheong JW, Lee ST, Min YH
- KMID: 2396073
- Yonsei Med J.
- 2009 Apr;50(2):280-283.
The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet... -
- CITED
-
- Close
- SHARE
-
- Close
- High-dose Versus Low-dose Cyclophosphamide in Combination with G-CSF for Peripheral Blood Progenitor Cell Mobilization
-
Ahn JS, Park S, Im SA, Yoon SS, Lee JS, Kim BK, Bang SM, Cho EK, Lee JH, Jung CW, Kim HC, Seong CM, Lee MH, Kim CS, Lee KS, Lee JA, Ahn MJ
- KMID: 1782234
- Korean J Intern Med.
- 2005 Sep;20(3):224-231.
- doi: 10.3904/kjim.2005.20.3.224
BACKGROUND: To compare the mobilizing effects and toxicities of two different doses of cyclophosphamide (CY) plus lenograstim (glycosylated G-CSF), we performed a prospective randomized study by enrolling patients suffering with... -
- CITED
-
- Close
- SHARE
-
- Close
